Related Experiment Video

Updated: Jul 12, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Temsirolimus for advanced renal-cell carcinoma

Nicola Fazio, Manuela Dettori, Katia Lorizzo

    The New England Journal of Medicine
    |September 7, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
    07:50

    Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

    Published on: May 25, 2018

    Related Experiment Videos

    Last Updated: Jul 12, 2026

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
    07:50

    Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

    Published on: May 25, 2018

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Rate and risk factors of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer: a retrospective analysis from a referral center.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

    Circulating tumor DNA to predict the risk of venous thromboembolism in locally advanced rectal cancer.

    Cancer treatment and research communications·2026

    Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.

    Endocrine-related cancer·2026

    Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows.

    Cancer treatment reviews·2026

    Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.

    Journal of neuroendocrinology·2026

    Syncope.

    The New England journal of medicine·2026

    Comparative safety of PICC-ports and chest ports in oncology: A monocentric retrospective cohort study.

    The journal of vascular access·2026

    Combinatorial effects of curcumin, morin, and phyllanthin in MDA-MB-231 and MCF-7 breast cancer cell lines.

    Indian journal of pharmacology·2026

    Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.

    Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

    Cost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.

    Expert review of pharmacoeconomics & outcomes research·2026

    Improving Cognitive Impairment in Cancer Patients With an Online Course in Mindfulness-Based Stress Reduction-A Randomized Controlled Trial.

    Psycho-oncology·2026

    Cytokine Release Syndrome Induced by Neoadjuvant Pembrolizumab in Early Triple-Negative Breast Cancer: A Case Report with Implications for Early Diagnosis and Management.

    Case reports in oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us